← FDA DRUG APPROVALS

FDA ANDA · ANDA211083

ERLOTINIB HYDROCHLORIDE

Sponsor: ACCORD HLTHCARE

APPLICATION
ANDA211083
TYPE
ANDA
ORIGINAL APPROVAL
2020-07-02
LATEST ACTION
2020-07-02
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

ERLOTINIB HYDROCHLORIDEDiscontinued
ERLOTINIB HYDROCHLORIDE EQ 150MG BASE · TABLET · ORAL
ERLOTINIB HYDROCHLORIDEDiscontinued
ERLOTINIB HYDROCHLORIDE EQ 25MG BASE · TABLET · ORAL
ERLOTINIB HYDROCHLORIDEDiscontinued
ERLOTINIB HYDROCHLORIDE EQ 100MG BASE · TABLET · ORAL

Approval history

2020-07-02UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →